Press Releases

Home/Press Releases

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its [...]

2020-06-15T08:25:00+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th [...]

2020-05-05T07:55:00+00:00Categories: Press Releases|Tags: |

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office has indicated its intent to grant the Company a patent [...]

2020-04-07T07:40:00+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

NEW YORK, Feb. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock [...]

2020-02-27T09:15:00+00:00Categories: Press Releases|Tags: |